AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Abcellera Biologics Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.318 Good afternoon and welcome to AppCellar's first quarter 2025 business update 00:00:05.318 -- 00:00:09.984 and conference call. My name is Jasmine and I will facilitate the audio portion of today's 00:00:09.984 -- 00:00:14.751 interactive broadcast. All lines will be muted during the presentation portion of the 00:00:14.751 -- 00:00:18.236 call with the opportunity for questions and answers at the end. 00:00:18.236 -- 00:00:22.922 If you would like to ask a question, press star one on your telephone keypad. 00:00:22.922 -- 00:00:27.748 If any assistance is needed during the call, please press star zero to speak with an 00:00:27.748 -- 00:00:32.873 operator. At this time, I would like to turn the call over to Trent Steinmart, 00:00:32.873 -- 00:00:36.177 Abcelera's Chief Legal and Compliance Officer. 00:00:36.177 -- 00:00:38.497 You may proceed. 00:00:39.220 -- 00:00:43.986 Thank you. Hello, everyone. Thank you for joining us for Abcelera's first quarter 2025 00:00:43.986 -- 00:00:49.391 earnings call. I'm Trent Steinmart, Abcelera's Chief Legal and Compliance Officer. 00:00:49.391 -- 00:00:54.097 Dr. Carl Hansen, Abcelera's President and Chief Executive Officer, and Andrew Booth, 00:00:54.097 -- 00:00:57.845 Abcelera's Chief Financial Officer, are joining me on today's call. 00:00:57.845 -- 00:01:02.190 During this call, we anticipate making projections and forward-looking statements based 00:01:02.190 -- 00:01:06.435 on our current expectations and according to the safe harbor provisions of the Private 00:01:06.435 -- 00:01:10.480 Securities Litigation Reform Act of 1995. 00:01:10.480 -- 00:01:14.845 Our actual results could differ materially due to several factors outlined in our latest 00:01:14.845 -- 00:01:19.851 Form 10-K and s...